*Chemotherapy: doxorubicin, paclitaxel x3 paclitaxel x4 cyclophosphamide, methotrexate, 5-FU x3
‡
Hormone receptor-positive patients received adjuvant tamoxifen
HER2-positive LABC
(IHC 3+ or FISH+)
HER2-negative LABC
(IHC 0/1+)
Chemotherapy*
Chemotherapy*
Trastuzumab +
chemotherapy*
Surgery followed by radiotherapy
‡
Trastuzumab continued
to week 52
n=115
n=113
n=99
19 patients crossed
over to trastuzumab
NOAH: phase III, open-label trial of
neoadjuvant trastuzumab
